BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 21267586)

  • 41. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytogenetic prognostication within medulloblastoma subgroups.
    Shih DJ; Northcott PA; Remke M; Korshunov A; Ramaswamy V; Kool M; Luu B; Yao Y; Wang X; Dubuc AM; Garzia L; Peacock J; Mack SC; Wu X; Rolider A; Morrissy AS; Cavalli FM; Jones DT; Zitterbart K; Faria CC; Schüller U; Kren L; Kumabe T; Tominaga T; Shin Ra Y; Garami M; Hauser P; Chan JA; Robinson S; Bognár L; Klekner A; Saad AG; Liau LM; Albrecht S; Fontebasso A; Cinalli G; De Antonellis P; Zollo M; Cooper MK; Thompson RC; Bailey S; Lindsey JC; Di Rocco C; Massimi L; Michiels EM; Scherer SW; Phillips JJ; Gupta N; Fan X; Muraszko KM; Vibhakar R; Eberhart CG; Fouladi M; Lach B; Jung S; Wechsler-Reya RJ; Fèvre-Montange M; Jouvet A; Jabado N; Pollack IF; Weiss WA; Lee JY; Cho BK; Kim SK; Wang KC; Leonard JR; Rubin JB; de Torres C; Lavarino C; Mora J; Cho YJ; Tabori U; Olson JM; Gajjar A; Packer RJ; Rutkowski S; Pomeroy SL; French PJ; Kloosterhof NK; Kros JM; Van Meir EG; Clifford SC; Bourdeaut F; Delattre O; Doz FF; Hawkins CE; Malkin D; Grajkowska WA; Perek-Polnik M; Bouffet E; Rutka JT; Pfister SM; Taylor MD
    J Clin Oncol; 2014 Mar; 32(9):886-96. PubMed ID: 24493713
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
    Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
    Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
    Blüml S; Margol AS; Sposto R; Kennedy RJ; Robison NJ; Vali M; Hung LT; Muthugounder S; Finlay JL; Erdreich-Epstein A; Gilles FH; Judkins AR; Krieger MD; Dhall G; Nelson MD; Asgharzadeh S
    Neuro Oncol; 2016 Jan; 18(1):126-31. PubMed ID: 26254476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transcriptional repressor REST drives lineage stage-specific chromatin compaction at
    Dobson THW; Tao RH; Swaminathan J; Maegawa S; Shaik S; Bravo-Alegria J; Sharma A; Kennis B; Yang Y; Callegari K; Haltom AR; Taylor P; Kogiso M; Qi L; Khatua S; Goldman S; Lulla RR; Fangusaro J; MacDonald TJ; Li XN; Hawkins C; Rajaram V; Gopalakrishnan V
    Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
    Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD
    Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
    Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
    J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
    Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Subgrouping Based on Immunohistochemistry in Medulloblastoma: a Single-Center Experience.
    Babaoglu B; Hanalioglu S; Varan A; Oguz KK; Bilginer B; Dolgun A; Soylemezoglu F
    Turk Neurosurg; 2024 Jan; ():. PubMed ID: 38874255
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SMARCA4/Brg1 coordinates genetic and epigenetic networks underlying Shh-type medulloblastoma development.
    Shi X; Wang Q; Gu J; Xuan Z; Wu JI
    Oncogene; 2016 Nov; 35(44):5746-5758. PubMed ID: 27065321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
    Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
    Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma.
    Vaillant C; Valdivieso P; Nuciforo S; Kool M; Schwarzentruber-Schauerte A; Méreau H; Cabuy E; Lobrinus JA; Pfister S; Zuniga A; Frank S; Zeller R
    PLoS One; 2015; 10(4):e0124870. PubMed ID: 25901736
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas.
    Wang YX; Wu H; Ren Y; Lv S; Ji C; Xiang D; Zhang M; Lu H; Fu W; Liu Q; Yan Z; Ma Q; Miao J; Cai R; Lan X; Wu B; Wang W; Liu Y; Wang DZ; Cao M; He Z; Shi Y; Ping Y; Yao X; Zhang X; Zhang P; Wang JM; Wang Y; Cui Y; Bian XW
    Signal Transduct Target Ther; 2022 Mar; 7(1):72. PubMed ID: 35273141
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteomic profiling of medulloblastoma reveals novel proteins differentially expressed within each molecular subgroup.
    Narayan V; Jaiswal J; Sugur H; Sd S; Rao S; Chatterjee A; Gowda H; A A; Somanna S; Santosh V
    Clin Neurol Neurosurg; 2020 Sep; 196():106028. PubMed ID: 32580068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.
    Keil VC; Warmuth-Metz M; Reh C; Enkirch SJ; Reinert C; Beier D; Jones DTW; Pietsch T; Schild HH; Hattingen E; Hau P
    AJNR Am J Neuroradiol; 2017 Oct; 38(10):1892-1898. PubMed ID: 28798218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    Lee C; Lee J; Choi SA; Kim SK; Wang KC; Park SH; Kim SH; Lee JY; Phi JH
    BMC Cancer; 2018 May; 18(1):535. PubMed ID: 29739450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
    Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.